FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-978-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$212.96 million
Profitability
Miscellaneous
Employees461
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) posted its earnings results on Thursday, August, 8th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $1.75. The biopharmaceutical company had revenue of $191.57 million for the quarter, compared to the consensus estimate of $29.03 million. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The business's quarterly revenue was up 335.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.28) EPS. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
7 brokers have issued 12 month price targets for FibroGen's shares. Their predictions range from $40.00 to $84.00. On average, they expect FibroGen's share price to reach $62.6667 in the next year. This suggests a possible upside of 51.0% from the stock's current price. View Analyst Price Targets for FibroGen.
What is the consensus analysts' recommendation for FibroGen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.
Has FibroGen been receiving favorable news coverage?
Media coverage about FGEN stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a news impact score of 0.9 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for FibroGen.
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Mylan (MYL), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of FibroGen own?
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
- Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
- Dr. K. Peony Yu, Chief Medical Officer (Age 57)
- Mr. Julian N. Stern, Sec. (Age 94)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.45%), BlackRock Inc. (7.23%), BlackRock Inc. (7.17%), Hillhouse Capital Advisors LTD. (3.13%), Janus Henderson Group PLC (2.90%) and Janus Henderson Group PLC (2.90%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which institutional investors are selling FibroGen stock?
FGEN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Candriam Luxembourg S.C.A., Morgan Stanley, Price T Rowe Associates Inc. MD, Bank of America Corp DE, UBS Asset Management Americas Inc., Handelsbanken Fonder AB and Pinnacle Associates Ltd.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz and Thomas B Neff. View Insider Buying and Selling for FibroGen.
Which institutional investors are buying FibroGen stock?
FGEN stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Hillhouse Capital Advisors LTD., JPMorgan Chase & Co., Nuveen Asset Management LLC, Westfield Capital Management Co. LP, Invesco Ltd., Janus Henderson Group PLC and Janus Henderson Group PLC. View Insider Buying and Selling for FibroGen.
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $41.49.
How big of a company is FibroGen?
FibroGen has a market capitalization of $3.61 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.
What is FibroGen's official website?
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
